Associated Papers
Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.
Stekler JD et al.
Plos Medicine, 2018
29584723 (PubMed )
Supplement: pmed.1002537.s002.doc
Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
Koh Y et al.
Journal of Virology, 2011
Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Margot NA et al.
Antimicrobial Agents and Chemotherapy, 2010
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Ntemgwa M et al.
Antimicrobial Agents and Chemotherapy, 2007
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D et al.
Antiviral Therapy, 2004
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions.
Cabana M et al.
Virology, 2002
Transmission of antiretroviral-drug-resistant HIV-1 variants.
Yerly S et al.
Lancet (london, England), 1999
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
Maschera B et al.
The Journal of Biological Chemistry, 1996
Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
Pazhanisamy S et al.
The Journal of Biological Chemistry, 1996
Select a paper to view details